AKBA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKBA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Akebia Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.28.
Akebia Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.28.
Akebia Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.27.
During the past 3 years, the average EPS without NRI Growth Rate was 53.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 37.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 12 years, Akebia Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 53.70% per year. The lowest was -64.50% per year. And the median was 11.70% per year.
The historical data trend for Akebia Therapeutics's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | -2.36 | -2.78 | -1.70 | -0.52 | -0.28 |
Akebia Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EPS (Basic) | Get a 7-Day Free Trial | -0.04 | -0.14 | -0.06 | -0.08 | - |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Akebia Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-51.925 | - | 0) | / | 187.465 | |
= | -0.28 |
Akebia Therapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as
Basic EPS (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (0.614 | - | 0) | / | 189.930 | |
= | 0.00 |
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (NAS:AKBA) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Akebia Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Ellen Snow | officer: SVP, CFO and Treasurer | C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
Michel Dahan | officer: SVP, Chief Business Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Nicole R. Hadas | officer: SVP, General Counsel, Sec. | 20 PILGRAM DRIVE, WINCHESTER MA 01890 |
David A Spellman | officer: SVP, CFO and Treasurer | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Steven Keith Burke | officer: SVP, Chief Medical Officer | 82 WILLIS ROAD, SUDBURY MA 01776 |
John P. Butler | director, officer: CEO & President | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Violetta Cotreau | officer: SVP, Chief Accounting Officer | 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142 |
Ron Frieson | director | 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142 |
Dell Faulkingham | officer: CCO | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Leanne M Zumwalt | director | C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037 |
Maxine Gowen | director | |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Myles Wolf | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Karen L Tubridy | officer: SVP, Chief Development Officer | ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 11-20-2023
By PRNewswire • 11-01-2023
By PRNewswire • 07-05-2023
By PRNewswire • 08-17-2023
By PRNewswire • 08-01-2023
By PRNewswire • 01-09-2024
By PRNewswire • 06-30-2023
By PRNewswire • 07-28-2023
By PRNewswire • 10-03-2023
By PRNewswire • 09-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.